EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). How to break such a bottleneck becomes a pressing probl...
Saved in:
| Published in | Frontiers in oncology Vol. 9; p. 1044 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Frontiers Media S.A
11.10.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). How to break such a bottleneck becomes a pressing problem in cancer treatment. The epithelial-mesenchymal transition (EMT) is a dynamic process that governs biological changes in various aspects of malignancies, notably drug resistance. Progress in delineating the nature of this process offers an opportunity to develop clinical therapeutics to tackle resistance toward anticancer agents. Herein, we seek to provide a framework for the mechanistic underpinnings on the EMT-mediated acquisition of EGFR-TKI resistance, with a focus on NSCLC, and raise the question of what therapeutic strategies along this line should be pursued to optimize the efficacy in clinical practice.Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). How to break such a bottleneck becomes a pressing problem in cancer treatment. The epithelial-mesenchymal transition (EMT) is a dynamic process that governs biological changes in various aspects of malignancies, notably drug resistance. Progress in delineating the nature of this process offers an opportunity to develop clinical therapeutics to tackle resistance toward anticancer agents. Herein, we seek to provide a framework for the mechanistic underpinnings on the EMT-mediated acquisition of EGFR-TKI resistance, with a focus on NSCLC, and raise the question of what therapeutic strategies along this line should be pursued to optimize the efficacy in clinical practice. |
|---|---|
| AbstractList | Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). How to break such a bottleneck becomes a pressing problem in cancer treatment. The epithelial-mesenchymal transition (EMT) is a dynamic process that governs biological changes in various aspects of malignancies, notably drug resistance. Progress in delineating the nature of this process offers an opportunity to develop clinical therapeutics to tackle resistance toward anticancer agents. Herein, we seek to provide a framework for the mechanistic underpinnings on the EMT-mediated acquisition of EGFR-TKI resistance, with a focus on NSCLC, and raise the question of what therapeutic strategies along this line should be pursued to optimize the efficacy in clinical practice. Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). How to break such a bottleneck becomes a pressing problem in cancer treatment. The epithelial-mesenchymal transition (EMT) is a dynamic process that governs biological changes in various aspects of malignancies, notably drug resistance. Progress in delineating the nature of this process offers an opportunity to develop clinical therapeutics to tackle resistance toward anticancer agents. Herein, we seek to provide a framework for the mechanistic underpinnings on the EMT-mediated acquisition of EGFR-TKI resistance, with a focus on NSCLC, and raise the question of what therapeutic strategies along this line should be pursued to optimize the efficacy in clinical practice.Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular-targeted therapies in non-small-cell lung cancer (NSCLC). How to break such a bottleneck becomes a pressing problem in cancer treatment. The epithelial-mesenchymal transition (EMT) is a dynamic process that governs biological changes in various aspects of malignancies, notably drug resistance. Progress in delineating the nature of this process offers an opportunity to develop clinical therapeutics to tackle resistance toward anticancer agents. Herein, we seek to provide a framework for the mechanistic underpinnings on the EMT-mediated acquisition of EGFR-TKI resistance, with a focus on NSCLC, and raise the question of what therapeutic strategies along this line should be pursued to optimize the efficacy in clinical practice. |
| Author | Chen, Lijie Niu, Xing Zhu, Xuan Liu, Ling |
| AuthorAffiliation | 1 Institute of Translational Medicine, China Medical University , Shenyang , China 5 Department of Second Clinical College, Shengjing Hospital Affiliated to China Medical University , Shenyang , China 4 Department of College of Stomatology, China Medical University , Shenyang , China 3 Department of Third Clinical College, China Medical University , Shenyang , China 2 Department of Surgery, First Affiliated Hospital of China Medical University , Shenyang , China |
| AuthorAffiliation_xml | – name: 5 Department of Second Clinical College, Shengjing Hospital Affiliated to China Medical University , Shenyang , China – name: 3 Department of Third Clinical College, China Medical University , Shenyang , China – name: 1 Institute of Translational Medicine, China Medical University , Shenyang , China – name: 2 Department of Surgery, First Affiliated Hospital of China Medical University , Shenyang , China – name: 4 Department of College of Stomatology, China Medical University , Shenyang , China |
| Author_xml | – sequence: 1 givenname: Xuan surname: Zhu fullname: Zhu, Xuan – sequence: 2 givenname: Lijie surname: Chen fullname: Chen, Lijie – sequence: 3 givenname: Ling surname: Liu fullname: Liu, Ling – sequence: 4 givenname: Xing surname: Niu fullname: Niu, Xing |
| BookMark | eNp1kc1PGzEQxa0KVCjl3Osee9ngz127h0ooCjRqAhKkUm-W154NRhsb7E2l_vd1CEiAVF888rz3G4_eJ3QQYgCEvhA8YUyqsz4GO6GYqAkmmPMP6JhSxmvF2e-DV_UROs35HpfTiCJkH9ERI40kQtJjtJwtV_USnDcjuOrcPm59KsXs8uKmXv2cVzeQfR5NsFD5UF3dThfTb9US7J0JPm9yZYKrbsdU3GsP-TM67M2Q4fT5PkG_Lmar6Y96cX05n54vaiswHWuFmYNOGswBWmKw405Ah2UDouOiV1gB50zSRghqnZNNa4i01ijWgzO9Yydovue6aO71Q_Ibk_7qaLx-eohprU0avR1Ac4wFU852TkjOO-h6qqy1xBpMiFKqsL7vWQ_bbgPOQijrDG-gbzvB3-l1_KObVknZygL4-gxI8XELedQbny0MgwkQt1lTVgZR3mJWpGIvtSnmnKDX1o9m9HFH9oMmWO-S1btk9S5Z_ZRs8Z29871873-Ofzbkpow |
| CitedBy_id | crossref_primary_10_3389_fmed_2020_615981 crossref_primary_10_3892_ol_2023_13932 crossref_primary_10_2174_1568009621666210203110305 crossref_primary_10_1111_jcmm_16568 crossref_primary_10_1007_s12032_024_02413_6 crossref_primary_10_3390_ijms25094844 crossref_primary_10_1002_1878_0261_13094 crossref_primary_10_3389_fonc_2022_1008027 crossref_primary_10_3389_fphar_2024_1404687 crossref_primary_10_3892_ol_2021_12949 crossref_primary_10_1016_j_intimp_2021_107734 crossref_primary_10_3390_ijms222212496 crossref_primary_10_3390_ijms22168838 crossref_primary_10_1080_15384047_2022_2133332 crossref_primary_10_1002_1878_0261_13542 crossref_primary_10_1007_s12033_021_00443_3 crossref_primary_10_1155_2022_2786567 crossref_primary_10_1016_j_freeradbiomed_2022_03_003 crossref_primary_10_15188_kjopp_2024_10_38_5_154 crossref_primary_10_1111_jcmm_16217 crossref_primary_10_3389_fcell_2020_627436 crossref_primary_10_1016_j_bbamcr_2021_119016 crossref_primary_10_4143_crt_2022_078 crossref_primary_10_1186_s12885_021_07863_z crossref_primary_10_1186_s12935_021_01791_5 crossref_primary_10_1007_s10238_024_01355_7 crossref_primary_10_1111_cas_15687 crossref_primary_10_3390_cancers14112613 crossref_primary_10_1039_D3RA02347H crossref_primary_10_3389_fgene_2021_668040 crossref_primary_10_3389_fonc_2022_880478 crossref_primary_10_3389_fgene_2020_562868 crossref_primary_10_4236_jbm_2021_912009 crossref_primary_10_3390_md21120607 crossref_primary_10_1186_s12964_024_01742_3 crossref_primary_10_1016_j_critrevonc_2023_103966 crossref_primary_10_3390_ijms24021475 crossref_primary_10_3390_ph15030381 crossref_primary_10_1080_21655979_2021_2012951 crossref_primary_10_1038_s41586_021_03796_6 crossref_primary_10_18632_aging_204958 crossref_primary_10_1080_01443615_2023_2301324 crossref_primary_10_1007_s10555_023_10141_y crossref_primary_10_3390_biom10081159 crossref_primary_10_1177_08853282241228667 crossref_primary_10_1155_2022_4102666 crossref_primary_10_1155_2022_1377565 crossref_primary_10_1007_s00280_023_04572_1 crossref_primary_10_1038_s41392_022_01168_8 crossref_primary_10_1360_SSV_2021_0389 crossref_primary_10_1155_2022_9302403 crossref_primary_10_1159_000510103 crossref_primary_10_3389_fcell_2021_634371 crossref_primary_10_2147_OTT_S262049 crossref_primary_10_1016_j_biopha_2020_110965 crossref_primary_10_1016_j_prp_2022_154293 crossref_primary_10_1038_s41598_021_82068_9 crossref_primary_10_3390_md20120751 crossref_primary_10_1158_1535_7163_MCT_22_0263 crossref_primary_10_2174_1871520623666230417090504 crossref_primary_10_3389_fbioe_2022_929979 crossref_primary_10_3389_fgene_2022_882519 crossref_primary_10_1038_s41388_024_03220_z crossref_primary_10_1038_s41467_021_22759_z crossref_primary_10_1016_j_bioorg_2020_103811 crossref_primary_10_1016_j_heliyon_2024_e33106 crossref_primary_10_1038_s41417_020_00256_7 crossref_primary_10_1016_j_ijbiomac_2023_124144 crossref_primary_10_1080_01635581_2023_2272345 crossref_primary_10_1016_j_phymed_2023_154884 crossref_primary_10_1155_2021_3138046 crossref_primary_10_1016_j_jep_2025_119636 crossref_primary_10_2174_1871520622666220614115309 crossref_primary_10_2174_0115748928283132240103073039 crossref_primary_10_1039_D3MD00366C crossref_primary_10_1016_j_addr_2022_114504 crossref_primary_10_37349_etat_2021_00032 crossref_primary_10_1007_s13577_021_00556_6 crossref_primary_10_3390_jcm12041438 crossref_primary_10_1016_j_bbrc_2024_150395 crossref_primary_10_3892_ol_2022_13528 crossref_primary_10_1016_j_arr_2024_102576 crossref_primary_10_1089_bioe_2023_0007 crossref_primary_10_1186_s12885_021_08893_3 crossref_primary_10_4103_ecdt_ecdt_95_23 crossref_primary_10_3389_fmed_2021_649279 crossref_primary_10_1155_2020_2719739 crossref_primary_10_1016_j_ijbiomac_2021_09_089 crossref_primary_10_1016_j_prp_2024_155721 crossref_primary_10_3390_ijms26072957 crossref_primary_10_1016_j_heliyon_2023_e14001 crossref_primary_10_31083_j_fbl2810271 crossref_primary_10_3389_fonc_2024_1447678 crossref_primary_10_1371_journal_pcbi_1010690 crossref_primary_10_1177_15330338231178639 crossref_primary_10_3892_ijo_2022_5373 crossref_primary_10_1002_cnr2_2079 crossref_primary_10_1016_j_lfs_2021_119022 crossref_primary_10_1111_1759_7714_13906 crossref_primary_10_3389_fcell_2022_1010639 crossref_primary_10_1007_s10555_023_10123_0 crossref_primary_10_3389_fonc_2022_882292 crossref_primary_10_1186_s13020_022_00581_z crossref_primary_10_1515_hsz_2021_0341 crossref_primary_10_1097_JCMA_0000000000000438 crossref_primary_10_3389_fonc_2022_862462 crossref_primary_10_3390_ijms21114002 crossref_primary_10_1007_s10495_022_01751_y crossref_primary_10_1007_s10528_024_10961_9 crossref_primary_10_1097_COC_0000000000001088 crossref_primary_10_3390_cancers13153906 crossref_primary_10_3390_ijms232113237 crossref_primary_10_1111_cas_15701 crossref_primary_10_3389_fonc_2020_542007 crossref_primary_10_3390_ijms23010250 crossref_primary_10_1007_s12032_023_02125_3 crossref_primary_10_1111_1759_7714_13715 crossref_primary_10_1155_2021_6616547 crossref_primary_10_1080_17520363_2025_2453411 crossref_primary_10_1186_s40164_025_00616_9 crossref_primary_10_3390_cancers14133062 crossref_primary_10_18632_aging_204594 crossref_primary_10_1016_j_jphs_2021_01_003 crossref_primary_10_1016_j_lfs_2021_119608 crossref_primary_10_1155_2021_2721466 crossref_primary_10_3390_biomedicines9091200 crossref_primary_10_1016_j_jbc_2024_107994 crossref_primary_10_1080_01635581_2021_1957487 crossref_primary_10_5306_wjco_v15_i6_755 crossref_primary_10_3389_fonc_2022_908031 crossref_primary_10_3390_cells9122596 crossref_primary_10_1016_j_ejphar_2021_173983 crossref_primary_10_1186_s12885_021_07888_4 crossref_primary_10_3390_ijms23148025 crossref_primary_10_5306_wjco_v16_i3_103297 crossref_primary_10_1038_s41392_023_01383_x crossref_primary_10_1016_j_bbrc_2022_04_136 crossref_primary_10_3892_br_2024_1914 crossref_primary_10_3389_fonc_2020_01101 crossref_primary_10_1038_s41388_024_03130_0 crossref_primary_10_1016_j_ejps_2023_106372 crossref_primary_10_3390_genes11060623 crossref_primary_10_3892_ijo_2023_5530 crossref_primary_10_1038_s41392_020_00313_5 crossref_primary_10_1080_21655979_2021_1932225 crossref_primary_10_3389_fgene_2021_746666 crossref_primary_10_3390_cancers14081931 |
| Cites_doi | 10.18632/oncotarget.16350 10.1016/j.lungcan.2015.01.004 10.1158/1078-0432.CCR-14-1998 10.1016/j.ejca.2017.08.027 10.1038/sj.emboj.7601818 10.1016/j.canlet.2015.11.043 10.1016/j.ceb.2014.09.001 10.1007/s10637-014-0192-4 10.1016/j.omtn.2017.06.005 10.1016/j.canlet.2015.07.048 10.1038/bjc.2017.292 10.1158/0008-5472.CAN-15-0377 10.1016/j.canlet.2019.02.018 10.1038/nrm3598 10.1016/j.cllc.2016.07.007 10.1093/annonc/mdv276 10.1517/14728222.2014.975794 10.1186/s12943-016-0502-x 10.1158/1078-0432.CCR-14-1116 10.1016/S1470-2045(17)30679-4 10.1634/theoncologist.2015-0057 10.3892/or.2016.4811 10.1016/j.gene.2016.08.043 10.1016/j.ejca.2013.07.007 10.1200/JCO.2013.54.4932 10.1016/j.cell.2016.02.024 10.1038/ncomms12231 10.1016/j.lungcan.2015.11.013 10.1158/1078-0432.CCR-14-0947 10.1158/1078-0432.CCR-13-2200 10.1038/srep31086 10.1111/cas.13022 10.1056/NEJMra1703413 10.18632/oncotarget.15479 10.1016/j.trecan.2016.05.010 10.1016/j.lungcan.2015.12.007 10.1038/nrclinonc.2015.61 10.1007/s12012-014-9297-4 10.1093/annonc/mdu517 10.1038/bjc.2017.226 10.1158/1078-0432.CCR-13-2613 10.1016/j.ctrv.2017.11.002 10.1016/j.cell.2016.01.009 10.1002/med.21482 10.1038/nrd.2015.13 10.1126/scitranslmed.aac5272 10.1002/stem.2039 10.1158/0008-5472.CAN-12-4721 10.1002/stem.2406 10.1158/1078-0432.CCR-14-1234 10.3892/ijo.2016.3547 10.3322/caac.21262 10.1111/cas.12749 10.1158/1078-0432.CCR-14-2518 10.1016/j.ejca.2015.07.035 10.1007/s00280-019-03934-y 10.1016/j.tips.2016.09.003 10.1371/journal.pone.0149370 10.1080/0284186X.2016.1253866 10.1158/1078-0432.CCR-13-2235 10.1371/journal.pone.0172115 10.1007/s00109-016-1420-5 10.18632/oncotarget.16375 10.18632/oncotarget.6293 10.1093/annonc/mdv026 10.1016/j.ejca.2015.11.021 10.1126/science.aaa1348 10.1038/nrc3775 10.1016/j.canlet.2015.10.012 10.1007/s10637-016-0382-3 10.1021/acsmedchemlett.5b00001 10.1016/j.gendis.2014.10.004 10.1038/nrd4140 10.1186/1756-8722-7-1 10.1080/17460441.2016.1243525 10.1016/j.tcb.2015.07.012 10.1038/nrclinonc.2017.44 10.1016/j.trecan.2016.11.008 10.1016/j.ejca.2019.03.015 10.1038/nrd4253 10.2147/DDDT.S86621 10.1158/1078-0432.CCR-14-0607 10.1016/j.lungcan.2010.11.011 10.1038/nrd4252 10.18632/oncotarget.3389 10.1007/s12032-015-0578-y 10.1002/cam4.412 10.1158/1078-0432.CCR-14-3319 10.1007/s00280-015-2895-4 10.1016/j.lungcan.2015.10.008 10.1038/srep40847 10.1158/1535-7163.MCT-17-0148 10.1016/S1470-2045(11)70393-X 10.1371/journal.pone.0147344 10.14309/ctg.0000000000000056 10.1038/nrm3758 10.1038/s41388-018-0454-2 10.1016/j.addr.2017.07.013 10.1186/s12943-016-0576-5 10.1016/j.cell.2016.06.028 10.1158/1078-0432.CCR-14-1187 10.1007/s10637-014-0166-6 10.1371/journal.pone.0180383 10.1007/s11523-017-0543-0 10.1158/1078-0432.CCR-14-2797 10.1186/s13045-014-0087-z |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Zhu, Chen, Liu and Niu. Copyright © 2019 Zhu, Chen, Liu and Niu. 2019 Zhu, Chen, Liu and Niu |
| Copyright_xml | – notice: Copyright © 2019 Zhu, Chen, Liu and Niu. – notice: Copyright © 2019 Zhu, Chen, Liu and Niu. 2019 Zhu, Chen, Liu and Niu |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fonc.2019.01044 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2234-943X |
| ExternalDocumentID | oai_doaj_org_article_400539dcbd5844bebf29ccc1ca011999 PMC6798878 10_3389_fonc_2019_01044 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c502t-903deb8a04ee71a0d4d5eb086e5b45f909e443826552cdd867a18cca93fedafd3 |
| IEDL.DBID | M48 |
| ISSN | 2234-943X |
| IngestDate | Wed Aug 27 01:29:35 EDT 2025 Thu Aug 21 18:24:36 EDT 2025 Fri Jul 11 11:58:00 EDT 2025 Tue Jul 01 00:43:45 EDT 2025 Thu Apr 24 23:03:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-903deb8a04ee71a0d4d5eb086e5b45f909e443826552cdd867a18cca93fedafd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology Reviewed by: Jin-Yuan Shih, National Taiwan University, Taiwan; Bhumsuk Keam, Seoul National University Hospital, South Korea Edited by: Alfredo Addeo, Geneva University Hospitals (HUG), Switzerland |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2019.01044 |
| PMID | 31681582 |
| PQID | 2311924703 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_400539dcbd5844bebf29ccc1ca011999 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6798878 proquest_miscellaneous_2311924703 crossref_citationtrail_10_3389_fonc_2019_01044 crossref_primary_10_3389_fonc_2019_01044 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-10-11 |
| PublicationDateYYYYMMDD | 2019-10-11 |
| PublicationDate_xml | – month: 10 year: 2019 text: 2019-10-11 day: 11 |
| PublicationDecade | 2010 |
| PublicationTitle | Frontiers in oncology |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Narita (B46) 2017; 12 Marcucci (B57) 2016; 15 Shibue (B6) 2017; 14 Pützer (B54) 2017; 120 David (B17) 2016; 164 Owonikoko (B79) 2015; 21 Derynck (B21) 2014; 31 Kovacs (B63) 2015; 15 Sarker (B76) 2015; 21 Kim (B41) 2016; 91 Bai (B35) 2016; 11 Rosa (B101) 2016; 11 Hong (B94) 2015; 7 Lamouille (B8) 2014; 15 Hussmann (B28) 2017; 8 Rizvi (B105) 2015; 348 Colak (B58) 2017; 3 Zhou (B26) 2015; 6 Nieto (B15) 2016; 166 Li (B37) 2016; 93 Planchard (B73) 2017; 18 Tang (B44) 2016; 371 Xin (B86) 2018; 38 Rodón (B60) 2015; 33 Wagner (B87) 2015; 21 Andersson (B30) 2014; 13 Sato (B48) 2017; 7 Scagliotti (B66) 2015; 26 Gerber (B100) 2015; 90 Liu (B38) 2015; 7 Soucheray (B18) 2015; 75 Goldman (B88) 2015; 21 Tani (B68) 2019 Reck (B107) 2017; 377 Yin (B53) 2016; 594 Yamashita (B43) 2015; 4 Ke (B104) 2016; 37 Torre (B1) 2015; 65 Zhang (B31) 2016; 7 Messersmith (B83) 2015; 21 Gupta (B16) 2016; 164 Takebe (B32) 2015; 12 Li (B9) 2017; 117 Molife (B78) 2014; 7 LoConte (B82) 2015; 33 Yuan (B13) 2014; 7 Wong (B95) 2015; 26 Yamamoto (B75) 2017; 35 de Aberasturi (B50) 2016; 370 Pattabiraman (B51) 2014; 13 Chiorean (B84) 2015; 21 Rosell (B4) 2012; 13 Xie (B14) 2013; 49 Weng (B12) 2019; 38 Della (B34) 2015; 21 Pant (B80) 2016; 56 Chung (B10) 2011; 73 Liu (B49) 2015; 6 Serrano-Gomez (B98) 2016; 15 Leighl (B69) 2017; 18 Zhou (B3) 2015; 26 Garg (B102) 2015; 19 Pan (B103) 2015; 33 Deskin (B22) 2016; 6 Angevin (B93) 2014; 20 Li (B24) 2017; 16 Zeng (B42) 2016; 49 Della (B36) 2017; 8 Minami (B89) 2016; 107 Iams (B65) 2015; 21 Chakraborty (B96) 2017; 8 Lin (B56) 2016; 2 Hashida (B52) 2015; 106 Yuan (B29) 2015; 369 Lee (B11) 2017; 12 Fujiwara (B61) 2015; 76 Wang (B23) 2016; 36 Shien (B40) 2017; 16 Ling (B97) 2013; 12 Chen (B45) 2017; 8 Ciuleanu (B70) 2017; 117 Yoshida (B19) 2016; 11 Bergqvist (B72) 2017; 56 Herbertz (B59) 2015; 9 Tai (B91) 2015; 20 Krishnamurthy (B90) 2018; 62 Anagnostou (B106) 2015; 21 Ahmed (B92) 2019; 449 Denduluri (B25) 2015; 2 Sato (B55) 2016; 34 Giaccone (B64) 2015; 51 Briscoe (B33) 2013; 14 Holgersson (B71) 2015; 32 Gray (B99) 2014; 20 Langer (B67) 2014; 32 Yeo (B27) 2015; 87 Lee (B20) 2007; 26 McGowan (B77) 2019; 113 Li (B39) 2014; 20 Ye (B7) 2015; 25 Buonato (B5) 2014; 74 McKeage (B85) 2018; 13 Mutlu (B47) 2016; 94 Soria (B74) 2017; 86 Kelley (B62) 2019; 10 Gavai (B81) 2015; 6 Chen (B2) 2014; 14 |
| References_xml | – volume: 8 start-page: 33300 year: 2017 ident: B28 article-title: IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells publication-title: Oncotarget. doi: 10.18632/oncotarget.16350 – volume: 87 start-page: 311 year: 2015 ident: B27 article-title: Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations publication-title: Lung Cancer. doi: 10.1016/j.lungcan.2015.01.004 – volume: 21 start-page: 1859 year: 2015 ident: B79 article-title: A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-1998 – volume: 86 start-page: 186 year: 2017 ident: B74 article-title: A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2017.08.027 – volume: 26 start-page: 3957 year: 2007 ident: B20 article-title: TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA publication-title: EMBO J. doi: 10.1038/sj.emboj.7601818 – volume: 371 start-page: 301 year: 2016 ident: B44 article-title: Molecular mechanisms of microRNAs in regulating epithelial-mesenchymal transitions in human cancers publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.11.043 – volume: 31 start-page: 56 year: 2014 ident: B21 article-title: Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition publication-title: Curr Opin Cell Biol. doi: 10.1016/j.ceb.2014.09.001 – volume: 33 start-page: 357 year: 2015 ident: B60 article-title: Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer publication-title: Invest New Drugs. doi: 10.1007/s10637-014-0192-4 – volume: 8 start-page: 132 year: 2017 ident: B96 article-title: Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine publication-title: Mol Ther Nucleic Acids. doi: 10.1016/j.omtn.2017.06.005 – volume: 369 start-page: 20 year: 2015 ident: B29 article-title: Notch signaling: an emerging therapeutic target for cancer treatment publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.07.048 – volume: 117 start-page: 974 year: 2017 ident: B9 article-title: Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer publication-title: Br J Cancer. doi: 10.1038/bjc.2017.292 – volume: 75 start-page: 4372 year: 2015 ident: B18 article-title: Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-0377 – volume: 449 start-page: 45 year: 2019 ident: B92 article-title: Towards the first targeted therapy for triple-negative breast cancer: repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.02.018 – volume: 14 start-page: 416 year: 2013 ident: B33 article-title: The mechanisms of Hedgehog signalling and its roles in development and disease publication-title: Nat Rev Mol Cell Biol. doi: 10.1038/nrm3598 – volume: 18 start-page: 34 year: 2017 ident: B69 article-title: Phase 2 study of erlotinib in combination with linsitinib (OSI-906) or placebo in chemotherapy-naive patients with non-small-cell lung cancer and activating epidermal growth factor receptor mutations publication-title: Clin Lung Cancer. doi: 10.1016/j.cllc.2016.07.007 – volume: 26 start-page: 1877 year: 2015 ident: B3 article-title: Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) publication-title: Ann Oncol. doi: 10.1093/annonc/mdv276 – volume: 19 start-page: 285 year: 2015 ident: B102 article-title: Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer publication-title: Expert Opin Ther Targets. doi: 10.1517/14728222.2014.975794 – volume: 15 start-page: 18 year: 2016 ident: B98 article-title: Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications publication-title: Mol Cancer. doi: 10.1186/s12943-016-0502-x – volume: 21 start-page: 1044 year: 2015 ident: B87 article-title: A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-1116 – volume: 18 start-page: 1307 year: 2017 ident: B73 article-title: Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30679-4 – volume: 20 start-page: 1189 year: 2015 ident: B91 article-title: Targeting the WNT signaling pathway in cancer therapeutics publication-title: Oncologist. doi: 10.1634/theoncologist.2015-0057 – volume: 36 start-page: 589 year: 2016 ident: B23 article-title: HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma publication-title: Oncol Rep. doi: 10.3892/or.2016.4811 – volume: 594 start-page: 23 year: 2016 ident: B53 article-title: Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC publication-title: Gene. doi: 10.1016/j.gene.2016.08.043 – volume: 49 start-page: 3559 year: 2013 ident: B14 article-title: Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2013.07.007 – volume: 32 start-page: 2059 year: 2014 ident: B67 article-title: Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer publication-title: J Clin Oncol. doi: 10.1200/JCO.2013.54.4932 – volume: 164 start-page: 840 year: 2016 ident: B16 article-title: EMT: matter of life or death? publication-title: Cell. doi: 10.1016/j.cell.2016.02.024 – volume: 7 start-page: 12231 year: 2016 ident: B31 article-title: A genetic cell context-dependent role for ZEB1 in lung cancer publication-title: Nat Commun. doi: 10.1038/ncomms12231 – volume: 91 start-page: 15 year: 2016 ident: B41 article-title: Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer publication-title: Lung Cancer. doi: 10.1016/j.lungcan.2015.11.013 – volume: 21 start-page: 77 year: 2015 ident: B76 article-title: First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-0947 – volume: 20 start-page: 2192 year: 2014 ident: B93 article-title: A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-2200 – volume: 6 start-page: 31086 year: 2016 ident: B22 article-title: Requirement of HDAC6 for activation of Notch1 by TGF-beta1 publication-title: Sci Rep. doi: 10.1038/srep31086 – volume: 107 start-page: 1477 year: 2016 ident: B89 article-title: Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors publication-title: Cancer Sci. doi: 10.1111/cas.13022 – volume: 377 start-page: 849 year: 2017 ident: B107 article-title: Precision diagnosis and treatment for advanced non-small-cell lung cancer publication-title: N Engl J Med. doi: 10.1056/NEJMra1703413 – volume: 8 start-page: 23020 year: 2017 ident: B36 article-title: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR publication-title: Oncotarget. doi: 10.18632/oncotarget.15479 – volume: 2 start-page: 350 year: 2016 ident: B56 article-title: Resisting resistance: targeted therapies in lung cancer publication-title: Trends Cancer. doi: 10.1016/j.trecan.2016.05.010 – volume: 93 start-page: 35 year: 2016 ident: B37 article-title: Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT publication-title: Lung Cancer. doi: 10.1016/j.lungcan.2015.12.007 – volume: 12 start-page: 445 year: 2015 ident: B32 article-title: Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update publication-title: Nat Rev Clin Oncol. doi: 10.1038/nrclinonc.2015.61 – volume: 15 start-page: 309 year: 2015 ident: B63 article-title: Cardiac safety of TGF-beta receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study publication-title: Cardiovasc Toxicol. doi: 10.1007/s12012-014-9297-4 – volume: 26 start-page: 497 year: 2015 ident: B66 article-title: Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer publication-title: Ann Oncol. doi: 10.1093/annonc/mdu517 – volume: 117 start-page: 757 year: 2017 ident: B70 article-title: Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer publication-title: Br J Cancer. doi: 10.1038/bjc.2017.226 – volume: 20 start-page: 2714 year: 2014 ident: B39 article-title: Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-2613 – volume: 62 start-page: 50 year: 2018 ident: B90 article-title: Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2017.11.002 – volume: 164 start-page: 1015 year: 2016 ident: B17 article-title: TGF-beta tumor suppression through a lethal EMT publication-title: Cell. doi: 10.1016/j.cell.2016.01.009 – volume: 38 start-page: 870 year: 2018 ident: B86 article-title: Strategies to target the Hedgehog signaling pathway for cancer therapy publication-title: Med Res Rev. doi: 10.1002/med.21482 – volume: 15 start-page: 311 year: 2016 ident: B57 article-title: Epithelial-mesenchymal transition: a new target in anticancer drug discovery publication-title: Nat Rev Drug Discov. doi: 10.1038/nrd.2015.13 – volume: 7 start-page: 314ra185 year: 2015 ident: B94 article-title: AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.aac5272 – volume: 33 start-page: 2085 year: 2015 ident: B103 article-title: Concise review: targeting cancer stem cells using immunologic approaches publication-title: Stem Cells. doi: 10.1002/stem.2039 – volume: 74 start-page: 309 year: 2014 ident: B5 article-title: ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-4721 – volume: 34 start-page: 1997 year: 2016 ident: B55 article-title: Concise review: stem cells and epithelial-mesenchymal transition in cancer: biological implications and therapeutic targets publication-title: Stem Cells. doi: 10.1002/stem.2406 – volume: 21 start-page: 1002 year: 2015 ident: B88 article-title: Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-1234 – volume: 49 start-page: 700 year: 2016 ident: B42 article-title: Repression of Smad4 by miR205 moderates TGF-beta-induced epithelial-mesenchymal transition in A549 cell lines publication-title: Int J Oncol. doi: 10.3892/ijo.2016.3547 – volume: 65 start-page: 87 year: 2015 ident: B1 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J Clin. doi: 10.3322/caac.21262 – volume: 7 start-page: 2026 year: 2015 ident: B38 article-title: Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition publication-title: Am J Transl Res. – volume: 106 start-page: 1377 year: 2015 ident: B52 article-title: Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib publication-title: Cancer Sci. doi: 10.1111/cas.12749 – volume: 21 start-page: 4270 year: 2015 ident: B65 article-title: Molecular pathways: clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-2518 – volume: 51 start-page: 2321 year: 2015 ident: B64 article-title: A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2015.07.035 – year: 2019 ident: B68 article-title: A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients publication-title: Cancer Chemother Pharmacol. doi: 10.1007/s00280-019-03934-y – volume: 37 start-page: 887 year: 2016 ident: B104 article-title: EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now? publication-title: Trends Pharmacol Sci. doi: 10.1016/j.tips.2016.09.003 – volume: 11 start-page: e0149370 year: 2016 ident: B35 article-title: Blockade of hedgehog signaling synergistically increases sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer cell lines publication-title: PLoS ONE. doi: 10.1371/journal.pone.0149370 – volume: 56 start-page: 441 year: 2017 ident: B72 article-title: Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer publication-title: Acta Oncol. doi: 10.1080/0284186X.2016.1253866 – volume: 20 start-page: 1644 year: 2014 ident: B99 article-title: A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-2235 – volume: 12 start-page: e0172115 year: 2017 ident: B46 article-title: Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and−200c publication-title: PLoS ONE. doi: 10.1371/journal.pone.0172115 – volume: 94 start-page: 629 year: 2016 ident: B47 article-title: miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance publication-title: J Mol Med (Berl) doi: 10.1007/s00109-016-1420-5 – volume: 8 start-page: 36787 year: 2017 ident: B45 article-title: Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer publication-title: Oncotarget. doi: 10.18632/oncotarget.16375 – volume: 6 start-page: 44332 year: 2015 ident: B26 article-title: Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer publication-title: Oncotarget. doi: 10.18632/oncotarget.6293 – volume: 26 start-page: 998 year: 2015 ident: B95 article-title: Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies publication-title: Ann Oncol. doi: 10.1093/annonc/mdv026 – volume: 56 start-page: 1 year: 2016 ident: B80 article-title: A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2015.11.021 – volume: 348 start-page: 124 year: 2015 ident: B105 article-title: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer publication-title: Science. doi: 10.1126/science.aaa1348 – volume: 14 start-page: 535 year: 2014 ident: B2 article-title: Non-small-cell lung cancers: a heterogeneous set of diseases publication-title: Nat Rev Cancer. doi: 10.1038/nrc3775 – volume: 370 start-page: 165 year: 2016 ident: B50 article-title: TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.10.012 – volume: 35 start-page: 37 year: 2017 ident: B75 article-title: Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer publication-title: Invest New Drugs. doi: 10.1007/s10637-016-0382-3 – volume: 6 start-page: 523 year: 2015 ident: B81 article-title: Discovery of clinical candidate BMS-906024: a potent pan-notch inhibitor for the treatment of leukemia and solid tumors publication-title: ACS Med Chem Lett. doi: 10.1021/acsmedchemlett.5b00001 – volume: 2 start-page: 13 year: 2015 ident: B25 article-title: Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance publication-title: Genes Dis. doi: 10.1016/j.gendis.2014.10.004 – volume: 12 start-page: 847 year: 2013 ident: B97 article-title: MicroRNAs and other non-coding RNAs as targets for anticancer drug development publication-title: Nat Rev Drug Discov. doi: 10.1038/nrd4140 – volume: 7 start-page: 1 year: 2014 ident: B78 article-title: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors publication-title: J Hematol Oncol. doi: 10.1186/1756-8722-7-1 – volume: 11 start-page: 1201 year: 2016 ident: B101 article-title: Approaches for targeting cancer stem cells drug resistance publication-title: Expert Opin Drug Discov. doi: 10.1080/17460441.2016.1243525 – volume: 25 start-page: 675 year: 2015 ident: B7 article-title: Epithelial-mesenchymal plasticity: a central regulator of cancer progression publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2015.07.012 – volume: 14 start-page: 611 year: 2017 ident: B6 article-title: EMT, CSCs, and drug resistance: the mechanistic link and clinical implications publication-title: Nat Rev Clin Oncol. doi: 10.1038/nrclinonc.2017.44 – volume: 3 start-page: 56 year: 2017 ident: B58 article-title: Targeting TGF-beta signaling in cancer publication-title: Trends Cancer. doi: 10.1016/j.trecan.2016.11.008 – volume: 113 start-page: 87 year: 2019 ident: B77 article-title: Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: a phase I study in patients with advanced non-small cell lung carcinoma publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2019.03.015 – volume: 13 start-page: 497 year: 2014 ident: B51 article-title: Tackling the cancer stem cells—what challenges do they pose? publication-title: Nat Rev Drug Discov. doi: 10.1038/nrd4253 – volume: 9 start-page: 4479 year: 2015 ident: B59 article-title: Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway publication-title: Drug Des Devel Ther. doi: 10.2147/DDDT.S86621 – volume: 21 start-page: 60 year: 2015 ident: B83 article-title: A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014 publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-0607 – volume: 73 start-page: 176 year: 2011 ident: B10 article-title: Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs publication-title: Lung Cancer. doi: 10.1016/j.lungcan.2010.11.011 – volume: 13 start-page: 357 year: 2014 ident: B30 article-title: Therapeutic modulation of Notch signalling–are we there yet? publication-title: Nat Rev Drug Discov. doi: 10.1038/nrd4252 – volume: 6 start-page: 10415 year: 2015 ident: B49 article-title: IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer publication-title: Oncotarget. doi: 10.18632/oncotarget.3389 – volume: 32 start-page: 129 year: 2015 ident: B71 article-title: A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer publication-title: Med Oncol. doi: 10.1007/s12032-015-0578-y – volume: 4 start-page: 551 year: 2015 ident: B43 article-title: Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells publication-title: Cancer Med. doi: 10.1002/cam4.412 – volume: 21 start-page: 4686 year: 2015 ident: B34 article-title: SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-3319 – volume: 76 start-page: 1143 year: 2015 ident: B61 article-title: Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors publication-title: Cancer Chemother Pharmacol. doi: 10.1007/s00280-015-2895-4 – volume: 90 start-page: 534 year: 2015 ident: B100 article-title: Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer publication-title: Lung Cancer. doi: 10.1016/j.lungcan.2015.10.008 – volume: 7 start-page: 40847 year: 2017 ident: B48 article-title: Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features publication-title: Sci Rep. doi: 10.1038/srep40847 – volume: 16 start-page: 2234 year: 2017 ident: B40 article-title: JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer publication-title: Mol Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0148 – volume: 13 start-page: 239 year: 2012 ident: B4 article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70393-X – volume: 11 start-page: e0147344 year: 2016 ident: B19 article-title: ZEB1 mediates acquired resistance to the epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer publication-title: PLoS ONE. doi: 10.1371/journal.pone.0147344 – volume: 10 start-page: e00056 year: 2019 ident: B62 article-title: A phase 2 study of galunisertib (TGF-beta1 receptor type i inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma publication-title: Clin Transl Gastroenterol. doi: 10.14309/ctg.0000000000000056 – volume: 15 start-page: 178 year: 2014 ident: B8 article-title: Molecular mechanisms of epithelial-mesenchymal transition publication-title: Nat Rev Mol Cell Biol. doi: 10.1038/nrm3758 – volume: 38 start-page: 455 year: 2019 ident: B12 article-title: Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI publication-title: Oncogene. doi: 10.1038/s41388-018-0454-2 – volume: 120 start-page: 89 year: 2017 ident: B54 article-title: Advances in cancer stem cell targeting: how to strike the evil at its root publication-title: Adv Drug Deliv Rev. doi: 10.1016/j.addr.2017.07.013 – volume: 16 start-page: 6 year: 2017 ident: B24 article-title: IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights publication-title: Mol Cancer. doi: 10.1186/s12943-016-0576-5 – volume: 166 start-page: 21 year: 2016 ident: B15 article-title: EMT: 2016 publication-title: Cell. doi: 10.1016/j.cell.2016.06.028 – volume: 21 start-page: 976 year: 2015 ident: B106 article-title: Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-1187 – volume: 33 start-page: 169 year: 2015 ident: B82 article-title: A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors publication-title: Invest New Drugs. doi: 10.1007/s10637-014-0166-6 – volume: 12 start-page: e0180383 year: 2017 ident: B11 article-title: Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells publication-title: PLoS ONE. doi: 10.1371/journal.pone.0180383 – volume: 13 start-page: 89 year: 2018 ident: B85 article-title: Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC publication-title: Target Oncol. doi: 10.1007/s11523-017-0543-0 – volume: 21 start-page: 2695 year: 2015 ident: B84 article-title: A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-14-2797 – volume: 7 start-page: 87 year: 2014 ident: B13 article-title: Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application publication-title: J Hematol Oncol. doi: 10.1186/s13045-014-0087-z |
| SSID | ssj0000650103 |
| Score | 2.5636718 |
| SecondaryResourceType | review_article |
| Snippet | Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which represent the... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 1044 |
| SubjectTerms | acquired resistance epidermal growth factor receptor tyrosine kinase inhibitors epithelial-mesenchymal transition non-small-cell lung cancer Oncology therapeutic strategies |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELYQA2JBPEV5yUgMLIakcZqYDaqWZxigSGyWHxdRCVJE2v_PXZKiZkAsbFHiJM53F9-dz_6OsRPUE4hCmwsihxLSdZ0wgQIRpAmEKoki6Wm-I3vs3bzIu9f4daHUF60Jq-mBa-DOJamJ8s56NJXSgs27yjkXOkNsZarauoc2byGYqsfgmAoY1Fw-GIWp83xSEGNhqM4oApEtM1Sx9bdczPYCyQWLM1xna42ryC_rLm6wJSg22UrWJMO3WDbIRiKrSm2A55eO1vTiweB6-CRG97f8CUpyDlGqfFzwx-f-Q_-CZ0BbfcflR8lN4fmcnBbKbfYyHIz6N6KpjiBcHHSnQgWRB5uaQAIkoQm89DFYjFAgtjLOFSIuKcvXi-Ou8z7tJSZMUV4qysGb3Ec7bLmYFLDLOP6UkIKkacsEnxLZCE2WMgbHAuekSTvsbA6Wdg11OFWweNcYQhC6mtDVhK6u0O2w058bPmvWjN-bXhH6P82I7ro6gUqgGyXQfylBhx3PZafx96CchylgMis1uq8UYuK41mFJS6itN7avFOO3imibMlRpku79Rxf32Sp9NJm9MDxgy9OvGRyiPzO1R5XqfgO9cvK2 priority: 102 providerName: Directory of Open Access Journals |
| Title | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies |
| URI | https://www.proquest.com/docview/2311924703 https://pubmed.ncbi.nlm.nih.gov/PMC6798878 https://doaj.org/article/400539dcbd5844bebf29ccc1ca011999 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkapeKp4iPKpF4sBlg9dex7tICJUoaXm4h5JIua32MYZIxSlxKsG_Z8ZxCpbKhYtl2bu2PLPzXn_D2EtcJ5BJXwkChxIqpEG4xIBIdAHSFFmmIuU7yrPR6Vx9XOSLP-2AOgI2N4Z21E9qvr4Y_vzx6x0K_FuKONHevq5WNYERSjOk4ELdZnfQLBUkpWXn62_Vck49DbbwPjfNO2D71MVJ5jrtGakWy7_ngPa3T_5lj6Z32WHnSPLjLefvsVtQ32f7ZVcqf8DKSTkTZduIAyI_DrTjF08mJ9NzMfv0gZ9DQ64j8pwva372Zfx5_IaXQD8CL5vvDXd15DvoWmgesvl0Mhufiq53ggh5km6ESbIIXrtEARTSJVHFHDzGL5B7lVcG-aGoBjjK8zTEqEeFkxq5abIKoqti9ojt1asaHjOOIgsaFCU1C3xK5jM0aMY51BQhKKcHbLgjlg0dsDj1t7iwGGAQoS0R2hKhbUvoAXt1PeFyi6nx76HvifrXwwgMu72wWn-1nWxZRZrExOAjelPKg69SE0KQwRGgnTED9mLHO4vCQxURV8PqqrHo3FIAilpvwIoeU3tv7N-pl99aGG6qX-lCP_nvmU_ZAX0pWUIpn7G9zfoKnqOLs_FHbWoAjycLedQu49-DZ_xH |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EMT-Mediated+Acquired+EGFR-TKI+Resistance+in+NSCLC%3A+Mechanisms+and+Strategies&rft.jtitle=Frontiers+in+oncology&rft.au=Zhu%2C+Xuan&rft.au=Chen%2C+Lijie&rft.au=Liu%2C+Ling&rft.au=Niu%2C+Xing&rft.date=2019-10-11&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=9&rft_id=info:doi/10.3389%2Ffonc.2019.01044&rft_id=info%3Apmid%2F31681582&rft.externalDocID=PMC6798878 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |